- Home
- BMRN vs HST Comparison
BMRN vs HST Comparison
Compare BMRN & HST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRN
- HST
- Stock Information
- Founded
- BMRN 1996
- HST 1927
- Country
- BMRN United States
- HST United States
- Employees
- BMRN N/A
- HST N/A
- Industry
- BMRN Biotechnology: Pharmaceutical Preparations
- HST Real Estate Investment Trusts
- Sector
- BMRN Health Care
- HST Real Estate
- Exchange
- BMRN Nasdaq
- HST Nasdaq
- Market Cap
- BMRN 10.0B
- HST 10.0B
- IPO Year
- BMRN 1999
- HST N/A
- Fundamental
- Price
- BMRN $51.52
- HST $17.80
- Analyst Decision
- BMRN Buy
- HST Buy
- Analyst Count
- BMRN 19
- HST 13
- Target Price
- BMRN $90.26
- HST $18.50
- AVG Volume (30 Days)
- BMRN 2.9M
- HST 8.5M
- Earning Date
- BMRN 10-27-2025
- HST 11-05-2025
- Dividend Yield
- BMRN N/A
- HST 5.04%
- EPS Growth
- BMRN 59.53
- HST 3.27
- EPS
- BMRN 2.68
- HST 1.06
- Revenue
- BMRN $3,094,001,000.00
- HST $5,950,000,000.00
- Revenue This Year
- BMRN $13.32
- HST $6.48
- Revenue Next Year
- BMRN $7.51
- HST $1.70
- P/E Ratio
- BMRN $19.20
- HST $16.86
- Revenue Growth
- BMRN 12.39
- HST 6.44
- 52 Week Low
- BMRN $50.76
- HST $12.22
- 52 Week High
- BMRN $73.51
- HST $19.37
- Technical
- Relative Strength Index (RSI)
- BMRN 40.53
- HST 69.06
- Support Level
- BMRN $51.80
- HST $15.61
- Resistance Level
- BMRN $53.49
- HST $16.92
- Average True Range (ATR)
- BMRN 1.84
- HST 0.44
- MACD
- BMRN -0.08
- HST 0.15
- Stochastic Oscillator
- BMRN 12.58
- HST 88.74
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
About HST Host Hotels & Resorts Inc.
Host Hotels & Resorts owns 81 predominantly urban and resort upper-upscale and luxury hotel properties representing over 43,000 rooms, mainly in the United States. Host recently sold off the company's interests in a joint venture owning a portfolio of hotels throughout Europe and also sold other joint ventures that owned properties in Asia and the United States. The majority of Host's portfolio operates under the Marriott and Starwood brands.